Company Details
  • Conbott Pharmtech Co.,Ltd.

  •  [Zhejiang,China]
  • Business Type:Manufacturer
  • Main Markets: Africa , Americas , Asia , Caribbean , East Europe , Europe , Middle East , North Europe , Oceania , Other Markets , West Europe , Worldwide
  • Exporter:71% - 80%
  • Certs:COS, ISO9001, ISO14010, FDA
  • Description:Raf Inhibitors,Raf Inhibitors Study,Raf Inhibitors Clinical Trials
Conbott Pharmtech Co.,Ltd. Raf Inhibitors,Raf Inhibitors Study,Raf Inhibitors Clinical Trials
Home > Products > Inhibitors > Raf Inhibitors
  • Title
  • All
Online Service
http://www.conbottpharm.comScan to visit

Raf Inhibitors

Product categories of Raf Inhibitors, we are specialized manufacturers from China, Raf Inhibitors, Raf Inhibitors Study suppliers/factory, wholesale high-quality products of Raf Inhibitors Clinical Trials R & D and manufacturing, we have the perfect after-sales service and technical support. Look forward to your cooperation!
View: List Grid
Anti Tumor Drugs Sorafenib Tosylate, CAS 475207-59-1
Anti Tumor Drugs Sorafenib Tosylate, CAS 475207-59-1

Model No. : 475207-59-1
Unit Price : 1

Leading manufacturer and supplier of chemicals Cas 475207 59 1 Sorafenib Tosylate in China We develop produce and distribute high quality pharmaceuticals intermediates special chemicals and other fine chemicals Sorafenib Tosylate Cas 475207 59 1 is...

China Manufacturer of Raf Inhibitors

China Raf Inhibitors Suppliers

Raf is an important signal transduction factor used in the mitogen- activated protein kinase MAPK pathway , undertake upstream Ras signal, transmitted to the downstream MEK / ERK, affecting the growth and differentiation of cells. MAPK pathway is one of the most important signals in the human body , it plays a very important role in the cytoplasmic activity and regulation of gene expression . if overexpression or mutation of subtype BRAF in the MAPK signaling pathway of Raf family , it may induce tumor development and progression. Currently Sorafenib is the most popular drug in Raf inhibitor family, has entered the fast-track passage of drug administration , is the first approved for clinical application of a multi-target targeted therapies in the world . It is used for the treatment of liver cancer cells, kidney cancer cells, locally recurrent or metastatic , progressive differentiated thyroid patients. With the gradual deepening of the study , there will be born a greater variety of more efficacy Raf Inhibitors Drug.
Conbottpharm could give you:
1. Best quality in your requirement
2. Competitive price in China market
3. Mature Technical support
4. Professional logistic support
All we want is win-win business. Send yr. inquiries, you will get it!
Copyright © 2021 Conbott Pharmtech Co.,Ltd. All rights reserved.
Communicate with Supplier?Supplier
Tommy Mr. Tommy
What can I do for you?